
EHA21: Sanofi builds case for rare disease drug sutimlimab a...
Sanofi's hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 data keep the drugmaker